Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIK1 | P39086 | 2/20 | 0.40 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.40 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.39 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.39 |
| ▸ | CPA1 | P15085 | 3/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.34 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.34 |
| ▸ | MMP2 | P08253 | 3/20 | 0.33 |
| ▸ | MMP3 | P08254 | 3/20 | 0.33 |
| ▸ | MMP7 | P09237 | 2/20 | 0.33 |
| ▸ | MMP1 | P03956 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11291119 | 0.83 | GRIK1 (0.43) | GRIK1GRIK2CPA1CYP2C19LMNA | |
| SCHEMBL112335 | 0.82 | GRIK1 (0.39) | GRIK1GRIK2RNPEPSLC7A5CPA1 | |
| SCHEMBL20953995 | 0.80 | RNPEP (0.50) | RNPEPSLC7A5CPA1ALDH1A1SLC1A3 | |
| SCHEMBL4795102 | 0.75 | GRIK1 (0.62) | GRIK1GRIK2RNPEPSLC7A5CPA1 | |
| SCHEMBL7305997 | 0.75 | GRIK1 (0.62) | GRIK1GRIK2RNPEPSLC7A5CPA1 | |
| SCHEMBL1885655 | 0.75 | GRIK1 (0.62) | GRIK1GRIK2RNPEPSLC7A5CPA1 | |
| SCHEMBL262006 | 0.72 | SLC7A5 (0.48) | RNPEPSLC7A5CPA1ALDH1A1SLC1A3 | |
| SCHEMBL262005 | 0.72 | SLC7A5 (0.48) | RNPEPSLC7A5CPA1ALDH1A1SLC1A3 | |
| SCHEMBL22367764 | 0.71 | GRIK1 (0.42) | GRIK1GRIK2RNPEPCPA1CYP2C19 | |
| SCHEMBL2536422 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE41289-E1 | Ultrashort acting hypnotic barbiturates | ARYX THERAPEUTICS, INC. (US) | 2010-04-27 | — | — | US | disclosed |
| US-7041673-B2 | High speed metabolism; antiepileptic agents; anesthetics; central nervous system disorders; anxiolytic agents | ARYX THERAPEUTICS, INC. (US) | 2006-05-09 | — | — | US | disclosed |
| US-20040167143-A1 | Ultrashort acting hypnotic barbiturates | MPM ASSET MANAGEMENT INVESTORS 2002 BVIII LLC | 2004-08-26 | — | — | US | disclosed |
| US-6683086-B2 | DERIVATIVES OF BARBITURIC AND THIOBARBITURIC ACIDS; RAPIDLY METABOLIZED BY BLOOD AND TISSUE ENZYMES TO FORM POLAR METABOLITES WITH NO HYPNOTIC ACTIVITY AND WHICH ARE RAPIDLY ELIMINATED | ARYX THERAPEUTICS | 2004-01-27 | — | — | US | disclosed |
| US-20030100575-A1 | Ultrashort acting hypnotic barbiturates | MPM ASSET MANAGEMENT INVESTORS 2002 BVIII LLC | 2003-05-29 | — | — | US | disclosed |
| EP-1276728-A2 | ULTRASHORT ACTING HYPNOTIC BARBITURATES | ARYx Therapeutics (US) | 2003-01-22 | — | — | EP | disclosed |
| US-6387914-B2 | PROVIDING SEDATIVE-HYPNOTIC TREATMENT BY ADMINISTERING BARBITURATE DERIVATIVE COMPOUND | ARYX THERAPEUTICS | 2002-05-14 | — | — | US | disclosed |
| US-20020013330-A1 | Ultrashort acting hypnotic barbiturates | MPM ASSET MANAGEMENT INVESTORS 2002 BVIII LLC | 2002-01-31 | — | — | US | disclosed |
| WO-2001081319-A2 | ULTRASHORT ACTING HYPNOTIC BARBITURATES | ARYX THERAPEUTICS (US) | 2001-11-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040167143-A1 | Ultrashort acting hypnotic barbiturates | GABRR1, GABRA1, GABRR2 | GRIK1 736/4885GRIK2 663/4885RNPEP 1167/4885 |
| US-20030100575-A1 | Ultrashort acting hypnotic barbiturates | GABRR1, GABRA1, GABRR2 | GRIK1 736/4885GRIK2 663/4885RNPEP 1167/4885 |
| US-20020013330-A1 | Ultrashort acting hypnotic barbiturates | GABRR1, GABRA1, GABRR2 | GRIK1 736/4885GRIK2 663/4885RNPEP 1167/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.